Merck Finalizes $3.4 Billion Acquisition of SpringWorks, Expands Strategic Focus on Rare Tumors

Merck has completed the acquisition of SpringWorks Therapeutics, Inc. – one of the most significant M&A transactions in the global biopharma sector in 2025. The deal is valued at $3.4 billion (€3 billion). With this acquisition, Merck is strategically expanding its Healthcare business into the area of rare tumor diseases and focusing on sustainable innovation-driven growth.

At the core of the deal is SpringWorks’ highly innovative portfolio, which includes two approved therapies:

• Ogsiveo® (Nirogacestat) – the first systemic treatment for desmoid tumors in adults
• Gomekli™ (Mirdametinib) – the first and only FDA-approved therapy for NF1-PN in both adults and children from age 2

“This is our largest acquisition in the Healthcare sector in nearly two decades, and it marks the beginning of an exciting new chapter,” said Belén Garijo, Chair of the Executive Board and CEO of Merck. The transaction will provide immediate revenue contribution and pave the way for long-term expansion – also by integrating Pimicotinib, an investigational therapy for TGCT.

Headquartered in Stamford, Connecticut, SpringWorks brings extensive expertise in targeted therapies for rare tumors. Combined with Merck’s global reach, these therapies are now positioned to benefit more patients worldwide.

“This move strengthens our leadership in rare tumors and expands global access to life-changing therapies,” said Danny Bar-Zohar, Member of the Executive Board and CEO of Healthcare at Merck.

SpringWorks’ shares are no longer traded on Nasdaq. Shareholders receive $47 per share in cash – Merck is now the sole owner.